Gilead Sciences (GILD) Consolidated Net Income (2009 - 2026)

Gilead Sciences (GILD) has reported Consolidated Net Income for 18 consecutive years, with -$10.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Consolidated Net Income fell 635.24% year-over-year to -$10.5 billion; the trailing twelve-month figure through Jun 2026 stood at -$2.9 billion (down 145.87% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
• Consolidated Net Income slipped to -$10.5 billion in Q2 2026 per GILD's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Consolidated Net Income topped out at $3.1 billion in Q3 2025 and bottomed at -$10.5 billion in Q2 2026.
• Historically, Consolidated Net Income has averaged $613.2 million across 5 years, with a median of $1.5 billion in 2023.
• The sharpest annual moves came in 2023 and 2026: Consolidated Net Income surged 8100.0% in 2023, then slumped 635.24% in 2026.
• Over 5 years, Consolidated Net Income stood at $1.6 billion in 2022, then fell by 13.29% to $1.4 billion in 2023, then grew by 25.85% to $1.8 billion in 2024, then surged by 41.86% to $2.5 billion in 2025, then tumbled by 515.19% to -$10.5 billion in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$10.5 billion, $2.0 billion, and $2.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.